A detailed history of Geode Capital Management, LLC transactions in Sage Therapeutics, Inc. stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,242,854 shares of SAGE stock, worth $6.97 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,242,854
Previous 1,239,097 0.3%
Holding current value
$6.97 Million
Previous $13.5 Million 33.41%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$7.02 - $13.08 $26,374 - $49,141
3,757 Added 0.3%
1,242,854 $8.96 Million
Q2 2024

Aug 09, 2024

BUY
$10.58 - $17.9 $505,364 - $855,011
47,766 Added 4.01%
1,239,097 $13.5 Million
Q1 2024

May 13, 2024

BUY
$18.62 - $26.95 $448,257 - $648,794
24,074 Added 2.06%
1,191,331 $22.3 Million
Q4 2023

Feb 13, 2024

BUY
$17.1 - $22.26 $1.06 Million - $1.37 Million
61,744 Added 5.59%
1,167,257 $25.3 Million
Q3 2023

Nov 13, 2023

BUY
$16.75 - $48.98 $635,964 - $1.86 Million
37,968 Added 3.56%
1,105,513 $22.8 Million
Q2 2023

Aug 11, 2023

BUY
$40.65 - $59.54 $1.11 Million - $1.63 Million
27,300 Added 2.62%
1,067,545 $50.2 Million
Q1 2023

May 15, 2023

BUY
$37.27 - $46.57 $1.22 Million - $1.53 Million
32,815 Added 3.26%
1,040,245 $43.6 Million
Q4 2022

Feb 13, 2023

BUY
$32.2 - $43.61 $1.4 Million - $1.9 Million
43,476 Added 4.51%
1,007,430 $38.4 Million
Q3 2022

Nov 14, 2022

BUY
$32.28 - $43.27 $309,274 - $414,569
9,581 Added 1.0%
963,954 $37.7 Million
Q2 2022

Aug 12, 2022

BUY
$27.52 - $37.99 $6.54 Million - $9.03 Million
237,691 Added 33.17%
954,373 $30.8 Million
Q1 2022

May 13, 2022

SELL
$30.71 - $45.71 $5.88 Million - $8.76 Million
-191,547 Reduced 21.09%
716,682 $23.7 Million
Q4 2021

Feb 11, 2022

BUY
$37.06 - $47.11 $1.24 Million - $1.57 Million
33,424 Added 3.82%
908,229 $38.6 Million
Q3 2021

Nov 12, 2021

BUY
$40.26 - $57.37 $4.07 Million - $5.8 Million
101,121 Added 13.07%
874,805 $38.8 Million
Q2 2021

Aug 13, 2021

BUY
$54.88 - $79.29 $6.38 Million - $9.22 Million
116,220 Added 17.68%
773,684 $44 Million
Q1 2021

May 12, 2021

BUY
$70.65 - $96.76 $1.37 Million - $1.87 Million
19,377 Added 3.04%
657,464 $49.2 Million
Q4 2020

Feb 12, 2021

BUY
$58.41 - $89.06 $2.14 Million - $3.27 Million
36,687 Added 6.1%
638,087 $55.2 Million
Q3 2020

Nov 13, 2020

SELL
$41.13 - $62.45 $781,470 - $1.19 Million
-19,000 Reduced 3.06%
601,400 $36.8 Million
Q2 2020

Aug 13, 2020

BUY
$25.95 - $43.15 $652,850 - $1.09 Million
25,158 Added 4.23%
620,400 $25.8 Million
Q1 2020

May 14, 2020

BUY
$26.15 - $77.24 $619,362 - $1.83 Million
23,685 Added 4.14%
595,242 $17.1 Million
Q4 2019

Feb 13, 2020

BUY
$60.18 - $154.77 $1.09 Million - $2.8 Million
18,067 Added 3.26%
571,557 $41.3 Million
Q3 2019

Nov 12, 2019

BUY
$140.29 - $189.96 $984,555 - $1.33 Million
7,018 Added 1.28%
553,490 $77.6 Million
Q2 2019

Aug 14, 2019

BUY
$157.85 - $183.09 $3.42 Million - $3.97 Million
21,686 Added 4.13%
546,472 $100 Million
Q1 2019

May 14, 2019

BUY
$89.33 - $163.65 $5.08 Million - $9.31 Million
56,869 Added 12.15%
524,786 $83.5 Million
Q4 2018

Feb 13, 2019

BUY
$81.94 - $139.71 $2.62 Million - $4.48 Million
32,033 Added 7.35%
467,917 $44.8 Million
Q3 2018

Nov 13, 2018

BUY
$138.11 - $169.04 $90,185 - $110,383
653 Added 0.15%
435,884 $61.6 Million
Q2 2018

Aug 14, 2018

BUY
$140.36 - $175.76 $1.03 Million - $1.29 Million
7,357 Added 1.72%
435,231 $68.1 Million
Q1 2018

May 15, 2018

BUY
$152.15 - $192.33 $7.15 Million - $9.04 Million
46,978 Added 12.33%
427,874 $68.9 Million
Q4 2017

Feb 13, 2018

BUY
$60.72 - $167.34 $4.42 Million - $12.2 Million
72,790 Added 23.62%
380,896 $62.7 Million
Q3 2017

Nov 14, 2017

BUY
$61.4 - $88.52 $916,210 - $1.32 Million
14,922 Added 5.09%
308,106 $19.2 Million
Q2 2017

Aug 14, 2017

BUY
N/A
293,184
293,184 $23.3 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $333M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.